Q3 ahead of expectations; guidance unchanged; attractive at current levels
03/11/26 -"bioMerieux reported a Q3 sales beat, with top-line growth driven by robust performance across both segments. Despite weak BIOFIRE respiratory panel sales, Molecular Biology delivered ..."
Pages
68
Language
English
Published on
03/11/26
You may also be interested by these reports :
03/11/26
Philips’ Q3 profitability exceeded expectations. Most segments contributed to topline growth, while the largest contributor, Diagnosis treatment, ...
03/11/26
FMC’s Q3 26 beat consensus, but the underlying picture is weak: organic revenue was flat, adjusted EBIT fell 6% and US SMTG worsened to -1.1%. FY26 ...
03/11/26
bioMerieux reported a Q3 sales beat, with top-line growth driven by robust performance across both segments. Despite weak BIOFIRE respiratory panel ...
02/11/26
Too hot to step in Exactly 12 months ago, SKAN (REDUCE; -3% DOWNSIDE) (Reduce, Switzerland) issued a profit warning citing multiple project delays, ...